Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): A large propensity score-matched population-based study

Hypomethylating agents (HMA) showed overall survival (OS) benefits in patients with higher-risk myelodysplastic syndromes (HR-MDS) in clinical trials. We conducted a retrospective cohort study of Surveillance, Epidemiology, and End Results (SEER)-Medicare data of patients ≥66 years diagnosed with re...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Leuk Lymphoma
Главные авторы: Davidoff, Amy J., Hu, Xin, Bewersdorf, Jan Philipp, Wang, Rong, Podoltsev, Nikolai A., Huntington, Scott F., Gore, Steven D., Ma, Xiaomei, Zeidan, Amer M.
Формат: Artigo
Язык:Inglês
Опубликовано: 2019
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7735409/
https://ncbi.nlm.nih.gov/pubmed/31878809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2019.1703970
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы